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Abstract Rational and objectives: Neuropeptide-Y (NPY), an orexigenic peptide that is 
released during periods of food restriction, has been shown to have a significant modulatory 
impact on drug-related behaviors.  We have previously reported that both acute food 
deprivation (FD) and NPY injections can reinstate extinguished drug-seeking behavior, a 
proposed animal model of relapse to drug abuse.  However, it is not clear whether the FD 
effect on drug seeking is dependent on NPY transmission.  Here we used the reinstatement 
model to assess the role of NPY Y1 and Y5-receptor-mediated transmission in FD-induced 
reinstatement of heroin seeking. Methods: Rats were trained to self-administer heroin for 10-
12 days (0.1 mg/kg/infusion/IV).  Animals then underwent extinction training followed by 
drug-seeking reinstatement tests under 21 hr of food deprivation and sated conditions. 
Results: Injections of a novel NPY Y5-receptor antagonist, Lu AA33810 (0.0, 1.0, or 30.0 
mg/kg/IP), resulted in a significant attenuation of food deprivation-induced reinstatement of 
extinguished heroin seeking. However, no significant effects on reinstatement were found for 
the Y1-receptor antagonist, BIBO 3304 (0.0, 5.0, or 10.0 nmol/ICV). Conclusions: These 
results suggest that while signals mediated through NPY Y1 receptors play a modest role in 
reinstatement, activation of Y5 receptors has a critical function in FD-induced reinstatement 
of heroin seeking behavior. 
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Dietary manipulations, such as food deprivation and food restriction, can modulate the 
rewarding, reinforcing, conditioned, and locomotor-activating effects of drugs of abuse. Both 
acute food deprivation (FD) and prolonged food restriction (FR) can facilitate drug-related 
behaviors across drugs of abuse (Bell et al. 1997; Campbell and Fibiger 1971; Deroche et al. 
1993), routes of administration (Cabeza de Vaca and Carr 1998; Carroll et al. 1979), and 
species (Comer et al. 1995; Rodefer and Carroll 1996). In addition, using the reinstatement 
procedure, a proposed animal model for relapse (Stewart and de Wit 1987), acute (24 hr) FD 
was shown to induce reinstatement of previously extinguished heroin and cocaine seeking 
under drug-free states in rats (Shalev et al. 2000; Shalev et al. 2003). Although advances have 
recently been made in the understanding of the brain mechanisms involved in the 
enhancement of drug reward by chronic FR (Carr 2007), the exact neuronal mechanisms 
underlying the effects of acute FD on drug seeking are not known. 
We, and others, have suggested that neuropeptidergic and/or hormonal signals that change in 
response to energy deficits, and which have been shown to modulate the reward pathway 
(Fulton et al. 2000), might underlie the effects of dietary manipulations on drug seeking (Carr 
et al. 2000; Shalev et al. 2001). Neuropeptide Y (NPY) is a 36 amino acid orexigenic peptide, 
which is a widely distributed peptide found throughout the CNS (Allen et al. 1983). NPY is 
released in response to periods of food scarcity (Bi and Moran 2003), and drives the initiation 
of food seeking and consummation of food. NPY has also been implicated in increasing the 
motivation to obtain food (Jewett et al. 1995), which could suggest that NPY signaling plays a 
role in appetitive reinforcement. We have recently shown that acute intracerebroventricular 
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(ICV) injections of NPY can reinstate extinguished heroin-seeking behavior, mimicking the 
effects of acute FD, and can also increase on-going cocaine self-administration and cocaine-
induced hyperactivity (Maric et al. 2008; Maric et al. 2009).  
Six NPY receptor subtypes (Y1-Y6) have been identified in the mammalian brain. Of these, 
the Y1 and Y5 receptor subtypes have been most frequently associated with ingestive 
behavior in mammals (Kalra et al. 1999). For example, ICV administration of NPY Y1-
receptor antagonists decreases food deprivation induced-feeding (Kask et al. 1998) and 
blockade of NPY Y5-receptor reduces food intake and body weight in diet-induced obese 
mice (Ishihara et al. 2006). Interestingly, these receptors have also been implicated in 
mediating psychoactive effects of drugs. For example, NPY Y1-receptor antagonists inhibit 
the locomotor enhancing effects of amphetamine (Kask and Harro 2000), and activation of 
NPY Y5-receptors has been shown to reduce morphine withdrawal precipitated by the opioid 
antagonist, naloxone (Woldbye et al. 1998).    
Our previous findings, and the studies described above, suggest that NPY might be an 
important mediator of the FD effect on reinstatement of drug seeking. Here we tested the 
effects of NPY transmission blockade on FD-induced reinstatement of heroin seeking, using 
the specific, high affinity NPY Y1-receptor antagonist, BIBO 3304 (Wieland et al. 1998), and 
the novel NPY Y5-receptor antagonist, Lu AA33810. Lu AA33810 was recently 
demonstrated to have very high affinity for the Y5 receptor as well as in vivo efficacy after 
systemic administration (Walker et al. 2009), and is thus considered a superior candidate for 
use in our procedure.  
Materials and methods 
Subjects 
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Eighty-eight Long-Evans male rats (Charles River, St. Constant, QC; 300-350 g) were used. 
Following recovery from intravenous (IV) and intracerebroventricular (ICV) guide 
cannulation surgery, rats were housed in operant conditioning chambers under a reversed  12 
hr light/dark cycle (lights off at 9:30 a.m.), throughout the experiment. Ad libitum access to 
water and food was available, except for the 21 hr food deprivation test condition. All rats 
were treated in accordance with the Canadian Council on Animal Care and approval was 
granted by the Concordia University Animal Research Ethics Committee. 
Surgery 
Rats were implanted with silastic catheters (Dow Corning, Midland, MI, USA) under 
anesthesia (xylazine and ketamine (10 + 100 mg/kg, intraperitoneal (IP)). Briefly, a small 
incision was made on the jugular vein’s surface allowing for the insertion of a catheter, which 
was then secured to the vein. The remaining segment of the catheter was directed 
subcutaneously to the top of the skull where it was attached to a modified 22-gauge cannula 
(Plastics One Industries, Roanoke, VA). During the same surgery, animals from Experiment 1 
were implanted with a 22-gauge cannula aimed 2 mm above the right lateral ventricle (AP - 
0.5, ML +1.4, DV -3.0, relative to bregma). Both cannulae were subsequently anchored to the 
skull with dental cement and jeweler screws. Following recovery from surgery, guide cannula 
placement was verified by demonstrating a short latency (<60 s) drinking response to 
angiotensin II (100 nmol, ICV). Throughout the experiment, the catheters were flushed daily 
with heparin and the antibiotic drug gentamicin in saline solution (7.5 IU + 12.0 μg/rat). 
Apparatus 
Operant conditioning chambers: Rats were individually housed in standard operant 
conditioning chambers (Med Associates, St. Albans, VT, or Coulbourn Instruments, 
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Allentown, PA, USA; 32.0 cm x 24.0 cm x 25.0 cm; 29.0 cm x 29.0 cm x 25.5 cm, 
respectively), which were kept in ventilated, sound-attenuating compartments. Each chamber 
contained two levers, which were placed 5 cm above the grid floor, and approximately 15 cm 
apart, on the right wall. The lever designated as ‘inactive’ remained extended, and presses on 
this lever did not result in any programmable consequences. The lever designated as ‘active’, 
extended at the beginning of each session and responses on that lever activated the infusion 
pump (Med Associates). Rats were attached to the infusion pump via a liquid swivel (Instech, 
Boulder, CO, USA) and a polyethylene-50 tubing shielded with a metal spring.  
Elevated plus maze: Located in a dimly lit room, the maze was made out of wood and 
consisted of four arms (11.5 x 55.0 cm) positioned at right angles 50 cm above the floor. The 
maze comprised of two arms considered as “Closed” arms, which had 40 cm high walls and 
two "Open" arms, which had 1.0 cm high ledges.  
ICV injections: The NPY Y1-receptor antagonist was injected using a microinfusion pump 
(Harvard Apparatus 11 plus, Holliston, MA) fitted with a 10 μl Hamilton syringe (Hamilton 
Company, Reno, NV).  
Drugs 
Heroin HCL (National Institute for Drug Abuse, Baltimore, MD) was dissolved in sterile 
water (5 mg/ml), and then further diluted individually for each rat with 0.9% saline solution to 
a dose of 0.1 mg/kg/infusion. For experiment 1, BIBO 3304 ((R)-N-[[4-
(aminocarbonylaminomethyl)-phenyl]methyl]-N2-(diphen ylacetyl)-argininamide 
trifluoroacetate; TOCRIS, MO) was dissolved in 30% dimethyl sulfoxide (DMSO) and 
distilled water to a concentration of either 2.5 nmol/ul or 5.0 nmol/ul. For experiment 2, Lu 
AA33810 ((N-[[trans-4-[(4,5-dihydro[1]benzothiepino[5,4-d]thiazol-2-
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yl)amino]cyclohexyl]methyl]-methanesulfonamide; Lundbeck Research USA, NJ) was 
dissolved in 5% DMSO, 1% methylcellulose and sterile saline.  NPY receptors antagonists’ 
doses were selected based on existing literature (Kask 2000; Walker et al. 2009). In addition, 
we verified in our laboratory that treatment with the high doses of the antagonists reduced 
free-feeding (BIBO 3304) and Y5-receptor-agonist-induced feeding (Lu AA33810). 
Procedure 
Self-administration training. Following a 24 hr habituation period in the operant conditioning 
chamber, all rats were trained to self-administer heroin with three 3 hr self-administration 
sessions per day under a fixed ratio 1 (FR-1), 20 s timeout schedule of reinforcement for a 
total of 10-12 days. The first daily session began shortly after the onset of the dark phase of 
the light/dark cycle. Each session began with the insertion of the levers into the chamber, the 
illumination of a houselight, and the activation of a cuelight/tone (2.9 Khz; 20 dB above 
background level) complex for 30 s. Subsequently, each response on the active lever resulted 
in the delivery of 0.1 mg/kg of heroin over 5 s, and the initiation of a 20 s timeout period.  
During the timeout period, lever presses were not reinforced, the houselight was turned off, 
and the cue-light/tone complex was turned on. At the end of each 3 hr session the active lever 
was retracted but the inactive lever remained in the chamber. 
Extinction. Following 10-12 days of self-administration training, rats were submitted to 
extinction training that followed the same procedure as the self-administration days, but 
consisted of only one 3 hr session/day. During extinction, heroin syringes were removed but 
the rats continued to be exposed to all the contextual and response-contingent cues present 
during the self-administration training phase. Beginning on the second day of extinction 
training, rats in experiment 1 received sham ICV injections. Rats in experiment 2 received 
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injections of saline (0.5 ml, IP). Extinction training continued for a minimum of 4 days and 
until animals reached an extinction criterion of 15 or less active lever presses per 3 hr session 
before conducting reinstatement tests.  
Reinstatement Test. Once rats met extinction criterion, they were exposed to two 3 hr 
reinstatement test sessions, which were preceded by either 21 hr of food-deprivation (food 
hoppers removed) or 21 hr of unlimited access to food, in a counterbalanced order. In 
experiment 1, rats were injected with the NPY Y1-receptor antagonist BIBO 3304 (0.0, 5.0 or 
10.0 nmol in 2 μl, ICV), 15 min before each reinstatement test. BIBO 3304 was injected over 
a period of 4 min using a 28-gauge injector that extends 3 mm below the tip of the guide 
cannula. The injector was retained in place for an additional 60 s after the injection to ensure 
the dispersion of the drug.  In experiment 2, 30 min before each reinstatement test, rats were 
injected with the NPY Y5-antagonist Lu AA33810 (0.0, 1.0, or 30 mg/kg, IP). Test sessions 
were separated by a minimum of two baseline days. 
Elevated plus maze. Rats were handled daily for 1 week prior to the elevated plus maze 
experiment, and habituated to the maze apparatus (10 min exposure) and ICV or IP injection 
procedures over 2 days. Immediately following the last habituation day, all rats were food-
deprived for 21 hr, by removing all food from the cages, with water available ad libitum. For 
experiment 1B, rats were randomly assigned to either the BIBO 3304  (10.0 nmol/rat/ICV, 
n=5) or vehicle (0.0 nmol/rat/ICV, n=5) group. Ten minutes following the injection, rats were 
brought from the animal facility to the testing room and were placed on the maze for 10 min. 
For experiment 2B, rats were randomly assigned to either the Lu AA33810  (30.0 mg/kg, IP, 
n=5) or vehicle (0.0 mg/kg, IP, n=5) group. Thirty minutes following the injection rats were 
brought from the animal facility to the testing room and were placed on the maze for 10 min. 
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For both experiments, following the maze test fecal boli was collected and counted, and the 
maze was wiped down with 70% ethanol to ensure environmental neutrality. Behavior on the 
plus maze was video-recorded and then scored by an observer who was unaware of treatment 
assignment. Two variables were observed and scored: 1. Time spent on closed arms, defined 
as time spent with all paws in the closed arm, or two hind paws in the closed arm and two 
front paws in middle or open arm. 2. Number of closed arm entries, defined as the number of 
closed arm entries from an open arm, or crossings from one closed arm to the other. 
Statistical Analyses 
Reinstatement data were analyzed with separate mixed design ANOVAs, which were 
conducted for each dependent variable (active and inactive lever responses) with a within-
subjects factor of condition (baseline, sated, and 21 hr food deprivation (FD)), and a between-
subjects factor of BIBO 3304 dose (0.0, 5.0, or 10.0 nmol/rat/ICV) for Experiment 1, or Lu 
AA33810 dose (0.0, 1.0 or 30.0 mg/kg, IP) for Experiment 2. Baseline condition was 
calculated by averaging the number of lever presses made during the last of day of extinction 
before each reinstatement test. Significant main effects were further analyzed using Fisher’s 
LSD post-hoc tests. Elevated plus maze data were analyzed using separate One-Way 
ANOVAs with the between-subjects factor of BIBO 3304 dose (0.0 or 10.0 nmol/rat/ICV; 
experiment 1B), or Lu AA33810 dose (0.0 or 30.0 mg/kg, IP; experiment 2B) for the two 
dependent variables described above. Time spent in closed arms was analyzed as percent time 
in closed arms (out of total session time). The critical cut-off point for significant results in all 
analyses was set at p 0.05. 
Results 
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Experiment 1A. Effects of treatment with the NPY Y1-receptor antagonist, BIBO 3304, on 
food-deprivation induced reinstatement of heroin seeking 
Eight rats were removed due to catheter blockage (n= 5), illness (n= 1) or poor self-
administration training (n= 2). One additional rat from the 5.0 nmol dose group was removed 
due to an extreme response rate on the active lever during the FD test (172 compared to a 
group average of 28.2). Final analyses included data from 29 rats in three BIBO 3304 dose 
groups, 0.0 nmol (n= 12), 5.0 nmol (n= 8) and 10.0 nmol (n= 9). On the last training day, the 
mean ± SEM number of infusions taken over the three 3 h sessions was 42.9 ± 3.6. The mean 
± SEM numbers of active and inactive lever responses made during the last day of training 
were 159.8 ± 34.2 and 11.9 ± 2.3, respectively. The mean ± SEM number of extinction 
training days prior to the first test session was 8.1 ± 0.7. 
Acute, 21 hr FD resulted in significant reinstatement of heroin seeking behavior, shown as an 
increase in the number of responses on the active lever, that was previously associated with 
drug delivery [condition effect; F(2, 52)= 17.00, p< 0.001; Figure 1a]. Post hoc comparisons 
found that the number of responses on the active lever during the FD condition was higher 
than in the baseline or sated conditions (p< 0.05). Pretreatment with 5.0 or 10.0 nmol of 
BIBO 3304 did not attenuate the FD effect on reinstatement of heroin seeking. In fact, 
responses on the active lever seemed to be increased during the FD test following treatment 
with the high dose of BIBO 3304 compared to vehicle (effect sizes: Cohen’s d = 0.7). 
No significant effects of condition or BIBO 3304 dose were found for inactive lever responses 
(Figure 1b). 
Experiment 1B. The effects of treatment with the NPY Y1-receptor antagonist, BIBO 3304 on 
performance in the elevated plus maze in food deprived rats. 
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Following experiment 1A, rats (n= 10) were housed in the animal facility on the same 
reversed light/dark cycle (lights off at 9:30 a.m., on at 9:30 p.m.) for a period of 2 weeks for 
drug washout and habituation. 
Although number of fecal boli was recorded, no statistical analysis was conducted, as most 
rats did not produce any. However, it is interesting to note that animals that did display 
excretion (n=2) were rats treated with BIBO 3304 (10.0 nmol/rat/ICV). BIBO 3304 treated 
rats spent significantly more time in the closed arms compared to vehicle treated rats [F(1,8)= 
5.37, p= 0.04; Figure 2a], and had more entries into closed arms, but this difference failed to 
reach statistical significance [F(1,8)= 3.70, p= 0.09; Figure 2b]. Nevertheless, the higher 
number of closed arms entries reflects a high number of crossings between the two closed 
arms in the BIBO 3304 treated group, and rules out attenuated general locomotion in this 
group as the reason for the longer time spent in the closed arms. 
Experiment 2A: Effects of treatment with the NPY Y5-receptor antagonist, Lu AA33810, on 
food-deprivation induced reinstatement of heroin seeking 
Three rats were removed due to illness (n= 2), and training failure (n= 1). Final analyses 
included data from 37 rats in three treatment groups of Lu AA33810 dose, 0.0 mg/kg (n=17), 
1.0 mg/kg (n=10), and 30.0 mg/kg (n=10).  On the last training day, the mean ± SEM number 
of infusions taken over the three 3 h sessions was 43.5 ± 3.9. The mean ± SEM numbers of 
active and inactive lever responses made during the last day of training were 126.7 ± 22.8 and 
15.6 ± 3.3, respectively. The mean ± SEM number of extinction training days prior to the first 
test session was 6.9 ± 0.4. 
A statistically significant higher number of active lever presses under the FD condition 
compared to the baseline and sated conditions was observed [condition: F(2, 68)= 18.54, p< 
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0.0001], regardless of treatment (Figure 3a). In addition, a statistically significant interaction 
between condition and Lu AA33810 dose for active lever presses was found [F(4, 68)= 2.68, 
p= 0.04], reflecting an attenuation of FD-induced reinstatement by pretreatment with Lu 
AA33810. Subsequent one-way ANOVAs, followed by post hoc tests, revealed a significant 
increase in active lever presses in rats treated with vehicle or the low dose of Lu AA33810 in 
the FD condition, compared to the baseline and sated conditions [F(2, 32)= 10.94, p= 0.0002; 
F(2, 18)= 8.39, p= 0.003, respectively], but not in rats treated with the high dose of Lu 
AA33810. Finally, within the FD condition, Lu AA33810 dose effect approached significance  
[F(2, 34)=2.78, p=0.08], and post hoc tests revealed a statistically significant difference in 
active lever responses between rats treated with the high dose Lu AA33810 and the low dose-
treated rats (p< 0.05). No significant effects for inactive lever presses were found (Figure 3b). 
Experiment 2B. The effects of treatment with the Y5 receptor antagonist, LU AA33810, on 
performance in the elevated plus maze in food deprived rats. 
Ten rats with heroin self-administration experience were kept in the animal facility under 
reversed light/dark cycle, as above, for 10 days to allow complete drug washout. The 
procedure for the elevated plus maze test followed the one used in experiment 1B. 
Since very few fecal boli were produced, these data were not recorded.  No statistically 
significant differences in percent time spent in the closed arms, or the number of entries into 
the closed arms were found (data not shown). 
Discussion 
The major finding in this report is that blockade of the NPY Y5-receptor with the novel 
antagonist, Lu AA33810, attenuated acute FD-induced reinstatement of heroin seeking. This 
result implies a critical role for Y5-receptor-mediated NPY transmission in FD-induced 
reinstatement. In contrast, pretreatment with BIBO 3304, an NPY Y1-receptor antagonist, did 
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not attenuate FD-induced reinstatement of heroin seeking, further emphasizing the specific 
role of the Y5-receptor in reinstatement of drug seeking. The attenuating effect of Lu 
AA33810 on drug seeking behavior was not due to general, non-specific effects of the 
antagonist, as inactive lever responding was not affected. Our results are consistent with 
studies that have shown that another Y5-antagonist, L-152,804, suppresses reward-related 
behavior. For example, it has been shown the oral delivery of L-152,804 attenuated alcohol-
self-administration in alcohol preferring rats (Schroeder et al. 2005). 
We have previously found that ICV injections of NPY, at doses known to stimulate feeding, 
increased cocaine self-administration and cocaine-induced locomotor activity, and induced 
reinstatement of previously extinguished heroin-seeking behavior in free-feeding animals 
(Maric et al. 2008; Maric et al. 2009). These findings imply that NPY mediates both the 
unconditioned and conditioned reinforcing effects of drugs of abuse and their associated cues. 
We have suggested that administration of NPY has the ability to activate or “mimic” a state of 
food-deprivation. Thus, it was concluded that NPY is involved in FD-induced reinstatement 
perhaps via a homeostatic mechanism expressed as a “hunger”-like state, or by direct 
augmentation of activity in the neuronal circuitry underlying the conditioned reinforcing 
properties of drug-associated cues. It was further speculated that NPY transmission might be 
necessary for the expression of FD-induced reinstatement. Our present findings support the 
latter speculation, albeit exclusively through the Y5-receptor. 
NPY Y5-receptor is expressed in high numbers in the hypothalamic areas known to regulate 
food intake such as the paraventricular nucleaus (PVN), arcuate nucleus (ARC), and in limbic 
regions (Morin and Gehlert 2006; Wolak et al. 2003). Although the NPY Y1-receptor is 
critical in the regulation of food intake, activation of the Y5 receptors has also been shown to 
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stimulate feeding (Kalra et al. 1999; Parker et al. 2000). Activation of hunger pathways 
traditionally associated with the hypothalamus, could modulate the saliency of reward-
associated cues for food or drug. Thus, Y5-receptor antagonism might have dampened hunger 
signals initiated by FD and thus inhibit FD-induced reinstatement of drug seeking. Indeed, 
treatment with the non-specific Y5-receptor antagonist, CGP71683A, significantly suppressed 
spontaneous nocturnal feeding and fasting-induced feeding (Kask et al. 2001). However, the 
role of Y5 receptor in the control of feeding has recently been questioned. Accumulating 
reports indicate that NPY Y5-receptor by itself does not have a major role in feeding 
behavior. For example, the Y5-receptor antagonist, NPY5RA-972, potently suppressed food 
intake induced by the Y5-receptor agonist cPP, but failed to attenuate NPY-induced feeding 
or spontaneous food intake (Turnbull et al. 2002). Similarly, Lu AA33810 was shown to have 
no effect on NPY-evoked food consumption (Walker et al. 2009). In addition, acute 
administration of a spironolactone Y5-receptor antagonist did not significantly reduce food 
intake or body weight in high-fat diet-fed mice, while treatment with a Y1-receptor antagonist 
resulted in a robust suppression of food intake and body weight (Mashiko et al. 2009). 
Finally, food deprivation seems to increase the expression of the Y1-receptor mRNA in the 
hypothalamus, while the expression of Y5 receptors is decreased (Widdowson et al. 1997; Xu 
et al. 1998).  
In conclusion, although we cannot completely rule out hunger-suppression as the underlying 
mechanism for the effect of the Y5 receptor antagonist on FD-induced reinstatement of heroin 
seeking, the findings described above make this interpretation highly unlikely.  
Another way for the Y5 receptor to modulate the reinstatement effect is through the mediation 
of anxiolytic responses. The present results, together with findings from previous studies, 
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suggest that Y5-receptor antagonism could be involved in reducing anxiety-producing states, 
an effect opposite to the one suggested for Y1 receptor antagonism described below. Systemic 
injections of Lu AA33810 at doses shown to decrease Y5 receptor agonist-induced feeding 
have been shown to produce anxiolytic and anti-depressant-like effects in rats (Walker et al. 
2009). These results suggest that antagonism of the Y5-receptor could counteract the 
stress/anxiety condition associated with FD, which is one of the suggested mechanisms 
underlying FD-induced reinstatement (Shalev et al. 2006). However, this is probably not the 
case here, as we found no anxiolytic effect for the high dose of Lu AA33810 in the elevated 
plus maze test. Moreover, identifying the underlying pathway for an anxiolytic or anti-stress 
effect appears problematic. The amygdala has been identified as the critical area for the 
anxiolytic effects of NPY (Heilig 2004). As expected, the amygdala contains Y1 and Y5 
receptors, with relatively higher Y5 receptor expression within basolateral nucleus (BLA) 
compared to the central amygdala (Wolak et al. 2003). Yet, it has been reported that the 
anxiolytic effects of NPY are specific to the BLA through exclusive activation of Y5 
receptors (Sajdyk et al. 2002), thus challenging the notion of NPY Y5-receptors in the BLA as 
the critical target for Lu AA33810 in our study.  
Finally, NPY has been shown to affect reward-related behaviors, as well as homeostatic 
feeding behavior (Brown et al. 2000). As previously mentioned, Y5 receptors have been 
shown to be involved in drug-reinforced behaviors (Schroeder et al. 2005), and thus it is 
possible that Y5 receptors mediate the effect of FD on drug-seeking through the modulation 
of reward pathways, and more specifically, the mesocorticolimbic dopaminergic (DA) 
pathway. DA projections from the ventral tegmental area (VTA), to nucleus accumbens 
(NAc) and to the prefrontal cortex (PFC) constitute this pathway, which is thought to 
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orchestrate motivational, affective and learning-based reward processing (Kelley and Berridge 
2002; Wise 2002). DA transmission has also been shown to be critically involved in the 
reinstatement of drug seeking behavior (Bossert et al. 2005), and we have recently 
demonstrated that activation of the DA D1 receptors is critical for acute FD-induced 
reinstatement of heroin seeking (Tobin et al. 2009). Consistent with this suggestion, it was 
reported that NPY Y5-receptor protein and mRNA are strongly expressed in mesolimbic 
regions such as the NAc (Wolak et al. 2003) and VTA (Morin and Gehlert 2006; Parker and 
Herzog 1999). More recently, it was reported that extracellular DA levels were enhanced in 
mesocorticolimbic projecting areas, including NAc, following central administration of either 
NPY or a Y5-selective agonist [cPP1-7,NPY19-23,Ala31,Aib32,Gln34]hPP (Quarta et al. 
2011). Thus, it is plausible that NPY mediates behaviors associated with dopamine release in 
the mesocorticolimbic pathway, including reinstatement of drug seeking, via activation of 
NPY Y5-receptors, and administration of Lu AA33810 might have interfered with this effect 
in our food deprived rats. 
The lack of attenuation of FD-induced reinstatement by the NPY Y1-recpetor antagonist, 
BIBO 3304, was somewhat surprising. Hypothalamic NPY Y1-receptors are thought to 
mediate the orexigenic properties of NPY, and blockade of these receptors reduces feeding 
behavior in free-feeding and diet-induced obese animals (Kanatani et al. 2001; Kask et al. 
1998). We have previously suggested that FD-induced reinstatement of drug seeking is 
mediated by activation of orexigenic pathways, and more specifically, NPY receptors, and 
reported that NPY administration results in reinstatement of heroin seeking (Maric et al. 
2008). We therefore expected the activation of the Y1-receptor to be critically involved in this 
effect.  
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Instead, it appeared that NPY Y1-receptor antagonism enhanced, rather than attenuated, the 
reinstatement effect, exclusively in the food-deprivation condition. Although statistical 
significance was not established and thus these data should be reviewed with caution, an 
impressive effect size found within the food-deprivation condition suggests that a synergistic 
effect between the food deprivation condition and Y1-receptor antagonist treatment might be 
present and thus merits consideration. 
It has been shown that NPY transmission reduces anxiety related phenomena (Heilig et al. 
1989), an effect thought to be mediated by the Y1 receptor, as ICV injections of BIBO 3304 
in a novel open field test, resulted in an increased defecation, a measure of anxiety, that 
occurred without affecting locomotion (Kask and Harro 2000). In addition, treatment with the 
Y1-receptor antagonist, BIBP 3226, induced conditioned place-avoidance (Kask et al. 1999). 
Moreover, blockade (experiment 1B) or antisense inhibition of NPY Y1-receptors 
(Wahlestedt et al. 1993), results in an increased anxiety as measured in the elevated plus-maze 
test. Pharmacologically-induced anxiety, for example, using yohimbine, is known to 
significantly reinstate extinguished drug seeking (Le et al. 2005; Shepard et al. 2004). We 
therefore suggest that the effects observed within the food deprivation condition in 
experiment 1A might have been a result of an increased anxiogenic experience associated 
with acute food deprivation, due to the treatment with the Y1-receptor antagonist. 
In conclusion, our findings suggest that NPY transmission via specific NPY receptor 
activation, namely, the Y5 receptors, is critical for the expression of FD-induced 
reinstatement of heroin seeking. Although the effect would appear to be consistent with 
involvement of NPY Y5 receptors in mesolimbic projection areas, the precise anatomical 
locus and cellular mechanism remain to be defined. 
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Figure legend 
Fig. 1 The effects of treatment with the NPY Y1-receptor antagonist, BIBO 3304, on acute 
food deprivation (FD)-induced reinstatement of heroin seeking.  Data shown are means 
(+SEM) of active (a) and inactive (b) lever responses during baseline and following pre-
treatment with Vehicle, 5.0, or 10.0 nmol/rat BIBO 3304 (ICV), in the sated condition and 
following 21 hr FD.  The baseline condition represents the average number of lever presses 
made, with no antagonist treatment, during the last extinction day prior to each test session. * 
p<0.05 compared to baseline and sated conditions 
Fig. 2 The effects of treatment with the NPY Y1-receptor antagonist, BIBO 3304, on 
performance in the elevated plus maze.  Data shown are mean (+SEM) time spent on the 
closed arms of the maze, as percent of total time (a), and mean (+SEM) number of entries into 
the closed arms (b), in the Vehicle and 10.0 nmol/rat (ICV) treatment groups. * p<0.05 
compared to Vehicle treatment. 
Fig. 3 The effects of treatment with the NPY Y5-receptor antagonist, Lu AA33810, on acute 
food deprivation (FD)-induced reinstatement of heroin seeking.  Data shown are means 
(+SEM) of active (a) and inactive (b) lever responses during baseline and following pre-
treatment with Vehicle, 1.0, or 30.0 mg/kg Lu AA33810 (IP), in the sated condition and 
following 21 hr FD.  The baseline condition represents the average number of lever presses 
made, with no antagonist treatment, during the last extinction day prior to each test session. * 
p<0.05 compared to baseline and sated condition. # p<0.05 compared to the 30.0 mg/kg 
group within the FD condition. 
 
